Loading...
Immune checkpoint inhibitors have activity in esophagogastric adenocarcinoma and are currently approved to treat patients with chemotherapy-refractory PD-L1–positive or microsatellite-instability–high cancers. However, a recent phase 3 trial showed that the anti–PD-L1 agent avelumab was not superior to physician's choice of chemotherapy for chemotherapy-refractory esophagogastric adenocarcinoma (JAVELIN Gastric 300; Ann Oncol 2018; 29:2052).
Investigators now report results of an industry-sponsored, international, open-label, randomized, phase 3 trial (JAVELIN Gastric 100) evaluating maintenance therapy with avelumab versus continuation of chemotherapy in the first-line treatment of patients with advanced gastric or gastroesophageal junction…